140 related articles for article (PubMed ID: 25628006)
1. A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of JDTic.
Buda JJ; Carroll FI; Kosten TR; Swearingen D; Walters BB
Neuropsychopharmacology; 2015 Aug; 40(9):2059-65. PubMed ID: 25628006
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic Relationships between Duration of Action of JDTic-like Kappa-Opioid Receptor Antagonists and Their Brain and Plasma Pharmacokinetics in Rats.
Owens SM; Pollard GT; Howard JL; Fennell TR; Snyder RW; Carroll FI
ACS Chem Neurosci; 2016 Dec; 7(12):1737-1745. PubMed ID: 27700049
[TBL] [Abstract][Full Text] [Related]
3. Kappa Antagonist JDTic in Phase 1 Clinical Trial.
Chavkin C; Martinez D
Neuropsychopharmacology; 2015 Aug; 40(9):2057-8. PubMed ID: 26174493
[No Abstract] [Full Text] [Related]
4. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
Vaughan D; Speed J; Medve R; Andrews JS
Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
[TBL] [Abstract][Full Text] [Related]
5. Single oral dose safety, tolerability, and pharmacokinetics of PNU-96391 in healthy volunteers.
Rodríguez CA; Azie NE; Adams G; Donaldson K; Francom SF; Staton BA; Bombardt PA
J Clin Pharmacol; 2004 Mar; 44(3):276-83. PubMed ID: 14973308
[TBL] [Abstract][Full Text] [Related]
6. Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity.
Munro TA; Berry LM; Van't Veer A; Béguin C; Carroll FI; Zhao Z; Carlezon WA; Cohen BM
BMC Pharmacol; 2012 May; 12():5. PubMed ID: 22642416
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers.
Davis J; Hackman F; Ndongo MN; Choo H; Lewis D; Tawadrous M; Goodrich J; Langdon G
Clin Ther; 2010 Oct; 32(11):1889-95. PubMed ID: 21095483
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacokinetics and tolerability of dotarizine in healthy subjects after single and multiple oral administration.
Farré M; Roset PN; Llorente M; Márquez M; Albet C; Pérez JA; Herrero E; Ortíz JA
Methods Find Exp Clin Pharmacol; 1997 Jun; 19(5):343-50. PubMed ID: 9379783
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
Geisser P; Banké-Bochita J
Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
[TBL] [Abstract][Full Text] [Related]
11. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacology of DP-b99 in healthy volunteers: first administration to humans.
Rosenberg G; Angel I; Kozak A
Br J Clin Pharmacol; 2005 Jul; 60(1):7-16. PubMed ID: 15963088
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist.
Carroll I; Thomas JB; Dykstra LA; Granger AL; Allen RM; Howard JL; Pollard GT; Aceto MD; Harris LS
Eur J Pharmacol; 2004 Oct; 501(1-3):111-9. PubMed ID: 15464069
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and pharmacological evaluation of JDTic analogs to examine the significance of the 3- and 4-methyl substituents.
Carroll FI; Gichinga MG; Kormos CM; Maitra R; Runyon SP; Thomas JB; Mascarella SW; Decker AM; Navarro HA
Bioorg Med Chem; 2015 Oct; 23(19):6379-88. PubMed ID: 26342544
[TBL] [Abstract][Full Text] [Related]
15. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.
Vaz-da-Silva M; Almeida L; Falcão A; Soares E; Maia J; Nunes T; Soares-da-Silva P
Clin Ther; 2010 Jan; 32(1):179-92. PubMed ID: 20171423
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers.
Lal R; Sukbuntherng J; Luo W; Chen D; Vu A; Tovera J; Cundy KC
Clin Ther; 2009 Aug; 31(8):1776-86. PubMed ID: 19808136
[TBL] [Abstract][Full Text] [Related]
17. A Double-Blind, Placebo-Controlled Trial Demonstrating the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of RTI-336.
Carroll FI; Kosten TR; Buda JJ; Wang L; Walters BB
Front Pharmacol; 2018; 9():712. PubMed ID: 30042675
[No Abstract] [Full Text] [Related]
18. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P
Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability and pharmacokinetics after single and multiple doses of preladenant (SCH420814) administered in healthy subjects.
Cutler DL; Tendolkar A; Grachev ID
J Clin Pharm Ther; 2012 Oct; 37(5):578-87. PubMed ID: 22676397
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
